ESMO 2024 - Overall Survival Data from the KEYNOTE-522 Trial with Dr. Peter Schmid

Dr. Peter Schmid presents the long-awaited overall survival data for Pembrolizumab in early-stage triple-negative breast cancer. His insights provide a crucial update on the impact of this therapy, highlighting significant advancements in treatment outcomes.